It is proposed that the ability of YSTB to slow the progression of rheumatoid arthritis may be related to modulating the JAK/STAT pathway by degrading the phosphorylated expression of JAK2, JAK3, and STAT3 proteins, whereas elevated SOCS3 protein expression. Here, JAK2 is linked to rheumatoid arthritis.